TRAF6 is required for BLyS-mediated NF-κB signaling in multiple myeloma cells
- 328 Downloads
Tumor necrosis factor receptor-associated factor 6 (TRAF6) transduces signals from members of the IL-1R/TLR and TNFR superfamilies to the transcription factors NF-κB and AP1. Elevated expression of the TNF family member B-lymphocyte stimulator (BLyS) in multiple myeloma (MM) has been described recently. However, the precise process by which BLyS signals in myeloma cell remains unknown. Here, we identified increased expression of TRAF6 in MM patient cells and the MM cell lines U266, RPMI8226, and KM3. Furthermore, rhBLyS induced TRAF6 up-regulation in these cells in a dose-dependent manner. Both the classical and alternative NF-κB pathways were activated by rhBLyS treatment. Depletion of TRAF6 by siRNA decreased levels of p-p65 and p-p100, even after stimulation with rhBLyS. Down-regulation of TRAF6 also abrogated rhBLyS-mediated cell viability. These findings suggest that TRAF6 is required for BLyS-mediated NF-κB signaling in myeloma cells and is a potential molecular therapeutic target in MM.
KeywordsTRAF6 BLyS BAFF NF-κB Multiple myeloma
Thanks for technical help from Ju Shaoqing, Ph.D., of Surgical Comprehensive Laboratory, Affiliated Hospital of Nantong University.
This work was supported by the National Youth Science Foundation (81201857) and the Natural Science Foundation of Jiangsu Province, China (BK2011388).
Compliance with ethical standards
Conflict of interest
All the authors do not have any conflict of interest to declare.
- 16.Romano A, Conticello C, Cavalli M. Immunological dysregulation in multiple myeloma microenvironment. Br J Haematol. 2014;2014:198539.Google Scholar
- 21.Secreto F, Manske M, Price-Troska T, Ziesmer S, Hodge LS, Ansell SM, et al. B-cell activating factor-receptor specific activation of tumor necrosis factor receptor associated factor 6 and the phosphatidyl inositol 3-kinase pathway in lymphoma B cells. Leuk Lymphoma. 2014;5:1884–92.CrossRefGoogle Scholar
- 23.Hideshima T, Neri P, Tassone P, Yasui H, Ishitsuka K, Raje N, et al. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. Mol Cell Biochem. 2006;12:5887–94.Google Scholar